Review

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective

Shuanghe Li¹,², Chongyang Bao¹,², Lingli Huang¹,* and Ji-Fu Wei¹,³,*

¹ Department of Pharmacy, Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Nanjing 210009, China
² Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China
³ Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing 211103, China
* Correspondence: lingli_huang@njmu.edu.cn (L.H.); weijifu@njmu.edu.cn (J.-F.W.)

Abstract: Triple-negative breast cancer (TNBC) is characterized by its high invasiveness, high metastasis and poor prognosis. More than one-third of patients with TNBC will present with recurrence or distant metastasis. Chemotherapy based on anthracyclines and taxanes is the standard treatment strategy for metastatic TNBC (mTNBC). Due to the lack of expression of progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2, therapies targeting these receptors are ineffective for mTNBC, thus special treatment strategies are required. In recent years, the development of new chemotherapy drugs, targeted drugs and immunotherapy drugs offers good prospects for the treatment of mTNBC. However, as these drugs are still in their infancy, several problems regarding the optimization and management of the clinical application of these new options should be considered. Pharmacists can play an important role in drug selection, drug therapy management, the management of adverse drug reactions and pharmacoeconomic evaluation. In this review, we summarized traditional treatment strategies, and discussed the efficacy and safety of novel agents approved in the last ten years and combination regimens for mTNBC, with the aim of providing management strategies for the clinical management of mTNBC from pharmacists’ perspective.

Keywords: metastatic triple-negative breast cancer; pharmacists’ perspective; chemotherapy; immunotherapy; management strategy

1. Introduction

Triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer, characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. TNBC accounts for approximately 15% to 20% of all breast cancers with a higher recurrence rate, greater metastatic potential, poorer prognosis and lower survival rate than other subtypes of breast cancer [2]. More than one-third of patients with TNBC can present distant metastasis including visceral organs and brain metastases in the third year after diagnosis [3]. As for metastatic TNBC (mTNBC), the median overall survival (OS) is only 12 to 18 months [4]. Chemotherapy has been the only systemic treatment option for mTNBC for many years, and standard chemotherapy regimens are usually based on anthracyclines or taxanes as the first-line treatment.

Chemotherapy drugs can directly kill tumor cells or inhibit the growth and proliferation of tumor cells. However, as well as attacking tumor cells, they also affect normal cells in the body, causing severe systemic toxic side effects. This condition limits the use of chemotherapeutic drugs. Tumor heterogeneity, genetic diversity, and chemoresistance also contribute to the poor response. Due to the lack of ER, PR, and HER2, TNBC is not sensitive to endocrine therapy and HER2 targeted therapy [4]. So, the treatment of mTNBC is limited by the lack of curative therapies, especially for patients who have failed both anthracycline and taxane therapy. With the development of high-throughput sequencing technology,
the heterogeneity and complexity of TNBC is better understood [5]. A number of new targets have been developed that may offer bright prospects for the treatment of mTNBC. These novel mechanisms include disruption of the three-dimensional structure of the DNA double strand by trophoblast cell surface antigen 2 (Trop-2) antibodies, inhibition of DNA damage repair, targeting of the phosphoinositide-3 kinase (PI3K) pathway, blocking the binding of tumor cells to T cells, regulating the cell cycle, and so on (Figure 1).

Figure 1. The mechanism of novel therapeutic drugs in mTNBC clinical studies. ADCs: antibody–drug conjugates; AR: androgen receptor; PARP: poly (ADP-ribose) polymerase; Trop-2: trophoblast cell-surface antigen 2; PD-1: programmed cell death-1; PD-L1: programmed cell death-ligand 1; VEGF: vascular endothelial growth factor; CHK: checkpoint kinase; CDK: cyclin-dependent kinase; ATR: ataxia telangiectasia and Rad3-related kinase; PI3K: phosphatidylinositol 3-kinase; MEK: mitogen-activated extracellular signal-regulated kinase; EGFR: epidermal growth factor; HER: human epidermal growth factor receptor. (a) In clinical trial; (b) Registered by Food and Drug Administration; (c) Registered by National Medical Products Administration; (d) Registered by European Medicines Agency.

More novel chemotherapy agents, targeted agents, and immunotherapy agents have been shown to be effective for the treatment of mTNBC, such as epothilone analogs, antibody drug conjugates (ADCs), poly (ADP-ribose) polymerase (PARP) inhibitors, programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 (PD-1) inhibitors, PI3K inhibitors, and androgen receptor antagonists. The agents approved for the treatment of mTNBC are shown in Figure 2 [6,7]. A detailed analysis of therapeutic trends, promising targets in mTNBC and biomarkers predicting the effectiveness of therapeutic strategies, as well as effective experimental compounds currently in clinical trials have been discussed in detail in other reviews [8,9]. Additionally, Lu et al. summarized the landmark clinical trials
in metastatic breast cancer mBC that have shaped the current standard of care of mBC to guide personalized treatment for mBC [10]. However, in clinical practice, several problems regarding optimizing and managing the clinical application of these new options should be considered to improve the safety and efficacy of treatment and quality of patients’ life. The role of pharmacists in the clinical application of new drugs is depicted in Figure 3. In this review, we summarized the traditional treatment strategies, and focused on the clinical management of novel drugs approved for mTNBC in terms of drug efficacy and safety, and their potential combination therapeutic strategies from pharmacists’ perspective, aiming to provide useful information for clinical application. The details of the literature search strategies are described in the Supplementary Materials.

Figure 2. The brief history of the development of drugs and current therapeutic strategies approved for mTNBC. mTNBC: metastatic triple-negative breast cancer; PARP: poly (ADP-ribose) polymerase; PD-L1: programmed death-ligand 1. (a) Single-agent chemotherapy is the preferred option, but combination regimens may be offered for symptomatic or immediately life-threatening disease (recommended by the European Society for Medical Oncology and American Society of Clinical Oncology). (b) Atezolizumab plus nab-paclitaxel was approved by the European Medicines Agency; pembrolizumab plus nab-paclitaxel and other chemotherapy was approved by the Food and Drug Administration. (c) There is insufficient evidence to determine the optimal sequencing of PARP inhibitors with other treatments. (d) Utidelone was approved by the National Medical Products Administration. Utidelone plus capecitabine was recommended by the Chinese Society of Clinical Oncology. (e) Food and Drug Administration and National Medical Products Administration approved.
In recent years, multiple studies showed that platinum-based chemotherapy regimens might play an important role in the chemotherapy of mTNBC as a first- or later-line treatment [13,14], but it seems to cause worse hematologic toxicity [15]. For example, the combination of cisplatin and docetaxel was found to be superior to the capecitabine plus docetaxel regimen as the first-line treatment for mTNBC with improved OS [16], and cisplatin combined with gemcitabine might be more effective than paclitaxel plus gemcitabine and could be an alternative or even preferred first-line chemotherapy strategy for mTNBC patients [17,18]. As the same time, the combination of platinum and PARP inhibitor veliparib also significantly improved PFS and showed a trend towards improved OS for patients with mTNBC [19]. Attention needs to be paid to the possible increased risk of adverse reactions in clinical practice, especially hematological toxicity. In addition, effective molecular markers screening for certain populations likely to benefit from platinum-based chemotherapy regimens may be the means to improve the efficacy, and this represents the focus of current research.

Figure 3. The role of pharmacists in the clinical application of novel antitumor drugs.

2. Traditional Chemotherapy Regimens

Systemic cytotoxic chemotherapy is the cornerstone of therapy in the treatment of patients with mTNBC and the best response to chemotherapy occurs primarily in the first line. Anthracyclines and taxanes-based chemotherapy combination regimens are preferred. Compared with monotherapy, combined chemotherapy regimens, such as the combination of anthracycline and cyclophosphamide and taxane combined with platin, usually have a higher objective remission rate (ORR) and progression-free survival (PFS) for patients with a high disease burden. However, they are more toxic, which adversely impact the patient’s quality of life [11]. Cardiotoxicity is the most serious adverse reaction of anthracyclines, limiting their use. When chemotherapy progresses or patients have poor tolerance to anthracyclines or taxanes, a variety of other cytotoxic drugs are available for the later treatment as monotherapy or combination regimens such as capcitabine, gemcitabine, and cisplatin. It is vital to understand the treatment purpose, prior chemotherapy regimens, disease burden, patient preferences, as well as the posology, in order to choose a suitable treatment strategy for each patient [12].

The role of pharmacists

- Provide drug information consultation service for medical staffs and update new drug information in time
- Participate in clinical decision-making and assist physicians in drug selection
- Prevent, identify, judge, manage and report adverse drug reactions
- Carry out economic evaluation of new drugs
- Strengthen the rational use of new drugs
- Engage in drug selection and guarantee drug supply
- Follow up and evaluate the clinical efficacy of new drugs
- Offer medication education and pharmaceutical care for patients

Figure 3. The role of pharmacists in the clinical application of novel antitumor drugs.
3. Novel Chemotherapy Agents

3.1. Utidelone

Epothilone analogs have been proved to have potent cytotoxic activity against multidrug resistance cells in preclinical research [20]. They can promote the polymerization of tubulin, stabilize the structure of microtubules and induce cell apoptosis. Ixabepilone is the first epothilone analog approved for the treatment of mBC, either alone or in combination with capecitabine [21]. However, ixabepilone is expensive and discontinuation is common due to its hematological toxicity and liver toxicity [22]. A new drug, utidelone, which showed promising results, has been approved in combination with capecitabine for the second-line and above treatment of mBC in China. Multiple clinical trials have shown that either compared to utidelone or capecitabine alone, the combination of utidelone and capecitabine could significantly improve PFS with 7.9 months versus 5.4 months and 8.44 months versus 4.27 months, respectively. However, peripheral neurotoxicity significantly increased in the combined group, with five times more than that of monotherapy [23–26] (Table 1). There were no differences in the incidence of neutropenia, leukopenia, or anemia between utidelone plus capecitabine and capecitabine monotherapy [23]. The most common adverse event with utidelone was peripheral sensory neuropathy, which was the main cause of dose reduction or discontinuation.

Based on the efficacy and safety results of utidelone in clinical trials, the following suggestions are made from the perspective of pharmacists. (1) Utidelone can also overcome the resistance to anthracyclines and taxanes with more favorable efficacy and lower toxicity than ixabepilone. Compared to ixabepilone, utidelone is less costly, showing the potential to replace ixabepilone in clinical application in the future. (2) The high incidence of peripheral neurotoxicity of utidelone may be due to the sensitization in patients previously treated with taxanes. The major clinical symptoms of peripheral neuropathy are pain and tingling of the hands and feet, which need to be distinguished from palmar-plantar erythrodysaesthesia induced by capecitabine. Clinically, the use of antioxidants such as glutathione, lipoic acid, vitamin C and cell-protective agents, such as amifostine and edaravone, to reduce the accumulation of chemotherapy drugs in the dorsal root ganglion and reduce the oxidative damage to peripheral neurons and nerve fibers may be considered. Moreover, acupuncture, cryotherapy, exercise therapy and ganglioside monosialic acid may also reduce severe peripheral neuropathy, but should be used with caution due to inconclusive efficacy [27–29]. (3) The absence of significant myelosuppressive toxicity is the most remarkable feature of utidelone compared to paclitaxel and ixabepilone, which may be a distinct advantage of utidelone. (4) The economics of the drug is an important factor that affects its benefits to patients. Available economic evaluations demonstrated that the cost-effectiveness of utidelone should be taken into account according to the economic level of different regions. Since the use of utidelone is at an early stage, more research is needed to determine whether it is a more economical option that will benefit more patients [30].

### Table 1. Clinical trials of novel chemotherapeutics approved for mTNBC.

| Phase | Intervention | Line of Therapy | Patients | N | Efficacy | Safety (AE ≥ Grade 3) |
|-------|--------------|-----------------|----------|---|----------|----------------------|
| Phase 2 trial [26] | Utidelone + capecitabine vs. utidelone | Second or later-line | mBC | 33 | ORR: 42.4% vs. 28.57%; PFS: 7.9 vs. 5.4 months | Peripheral neuropathy: 45.5% vs. 8.6%; hand-foot syndrome: 15.2% vs. 0%; hematologic toxicity: 6.1% vs. 7.1%; myalgia and arthralgia: 15.2% vs. 1.4 |
| Phase 3 trial [23] | Utidelone + capecitabine vs. capecitabine | Second or later-line | mBC refractory to anthracycline and taxane | 405 | PFS: 8.44 vs. 4.27 months | Peripheral sensory neuropathy: 22% vs. < 1%; palmar-plantar erythrodysaesthesia: 7% vs. 8% |
| Phase 1/2 trial [31] | Eribulin + olaparib | Second or later-line | Advanced or metastatic TNBC | 48 | ORR: 37.5%; PFS: 4.2 months; OS: 14.5 months | Leucopenia: 87.5%; anemia: 41.7; neutropenia: 87.5%; febrile neutropenia: 33.3%; diarrhea: 4.2% |
| Phase       | Intervention                                                                 | Line of Therapy         | Patients | Efficacy  | Safety (AE ≥ Grade 3)          |
|-------------|-------------------------------------------------------------------------------|-------------------------|----------|-----------|------------------------------|
| Phase 3     | Eribulin vs. TPC                                                             | Third or later-line     | mBC      | ORR: 12% vs. 5%; OS: 13.1 vs. 10.6 months; PFS: 3.7 vs. 2.2 months | Neutropenia: 21% vs. 14%; leucopenia: 12% vs. 5%; fatigue: 8% vs. 10%; peripheral neuropathy: 8% vs. 2%; dyspnea: 4% vs. 2% |
| Phase 3     | Eribulin vs. vinorelbine                                                       | Third or later-line     | mBC      | ORR: 30.7% vs. 16.9%; OS: 13.4 vs. 12.5 months; PFS: 2.7 vs. 1.4 months | Total: 88.3% vs. 90.2%; anemia: 2.3% vs. 18.3%; febrile neutropenia: 2.7% vs. 1.2% |
| Phase 3     | Eribulin vs. capecitabine                                                     | First-, second-, or third-line | mBC      | ORR: 11.0% vs. 11.5%; OS: 15.9 vs. 14.5 months; PFS: 4.1 vs. 4.2 months | Neutropenia: 24.6% vs. 4.2%; leukopenia:13.4% vs. 1.8%; Anemia: 2.0% vs. 0.9%; peripheral neuropathy: 6.4% vs. 0.9% |
| Phase 2     | Eribulin + gemcitabine                                                        | First- or second-line   | mTNBC    | ORR: 37.3%; OS: 14.5 months; PFS: 5.1 months | Aminotransferase elevation: 25%; Neutropenia: 23.8% |
| Phase 2     | Eribulin + bevacizumab                                                        | Second-line HER2-negative mBC | 58       | ORR: 24.6%; OS: 14.8 months; PFS: 6.2 months | Hypertension: 7%; neutropenia:7%; febrile neutropenia: 7% |
| Phase 2     | Eribulin                                                                     | First- or second-line   | mBC      | ORR: 43.8%; PFS: 8.3% | Neutropenia: 40.6%; peripheral neuropathy: 12.5%; fatigue: 12.5%; thrombocytopenia: 6.3% |
| Phase 2     | Eribulin                                                                     | Second-line mBC         | 53       | ORR: 20.8%; CBR: 26.4% | Neutropenia: 35.9%; leucopenia:17% |
| Phase 2     | Camrelizumab + apanitum + eribulin                                           | NR                      | Advanced TNBC | ORR: 37%; PFS: 8.1 months; DCR: 87% | Elevated AST/ALT: 17%; neutropenia: 30.4%; leucopenia: 13.0%; thrombocytopenia: 19.6% |
| Phase 2     | Eribulin + gemcitabine vs. Paclitaxel + gemcitabine                          | First-line HER2-negative mBC | 118      | ORR: 48.9% vs. 44.1%; the 6-months PFS rate: 72% vs. 73% | Neutropenia: 57.6% vs. 67.8%; neurotoxicity: 13.6% vs. 45.8% |
| Phase 1b/2  | Eribulin + pembrolizumab                                                      | First-line and later-line mTNBC | 167      | PD-L1+ vs. PD-L1−: (1) first-line: ORR: 34.5% vs. 16.1%; (2) second or later-line: ORR: 24.4% vs. 18.2% | Neutropenia: 26%; immune-related AE: 12% |

AE: adverse event; TNBC: triple-negative breast cancer; mBC: metastatic breast cancer; TPC: treatment of physician’s choice; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; DCR: disease control rate; CBR: clinical benefit rate.

### 3.2. Eribulin Mesylate

Eribulin has a different mode of action compared to taxanes and vinca alkaloids, as it inhibits dynamic instability by binding to a few high-affinity sites at the growth terminal of microtubules [33]. Its novel and unique mechanism of action, which exerts its antitumor effects mainly by preventing the growth of microtubules without affecting shortening and by segregating microtubulin as non-functional aggregates. Eribulin has strong antitumor activity against a variety of tumor cells and the ability to overcome taxane resistance conferred by β-tubulin mutations [42]. Unlike paclitaxel, it can improve the OS of taxane-resistant relapsed or mBC due to its unique mechanism. The EMBRACE clinical trial showed that eribulin achieved significantly superior OS [32], and was well tolerated in previously treated mBC [33]. It has been approved for the third-line treatment of mBC [43]. Substantial evidences supported eribulin as the third- or later-line treatment of mTNBC [33,44], but there is still controversy over whether eribulin can be used as a first- or second-line treatment for mTNBC. When used as first- or second-line therapy, eribulin monotherapy showed sufficient efficacy and the clinical benefit and tumor control rates were 56.3% and 78.1%, respectively [37]. However, eribulin is comparable to capecitabine.
monotherapy in OS or PFS for mBC patients [34]. Eribulin in combination with gemcitabine also demonstrated promising antitumor activity as first- or second-line therapy for mTNBC, with an ORR and PFS of 37.3% and 14.5 months, respectively. Moreover, the study also found that compared with BRCA pathogenic variants, BRCA wild-type patients had higher efficacy with an ORR of 41.5% versus 26.7% [35]. Compared with paclitaxel plus gemcitabine, eribulin plus gemcitabine chemotherapy had similar clinical benefits in terms of PFS, but had lower neurotoxicity [40]. In addition, the combination of eribulin and pembrolizumab showed good antitumor effect for both PD-L1 positive and negative tumors in mTNBC, but the ORR of PD-L1 positive tumor patients was higher than that of PD-L1 negative [41]. Neutropenia was the most common grade 3 adverse event. Peripheral neuropathy was the most common adverse event, leading to the discontinuation from eribulin. The details are shown in Table 1.

Although eribulin has been widely used in Western countries for a long time, it has only been approved in China and other Asian countries in recent years. Its use in clinical practice is limited. Based on the efficacy and safety of eribulin, the following points are available from pharmacists’ perspective. (1) Eribulin has similar efficacy to capecitabine, but the incidence of neutropenia, peripheral neurotoxicity and other adverse reactions is higher. Eribulin has no obvious advantage. (2) The combination of eribulin and gemcitabine has a relative advantage compared to paclitaxel plus gemcitabine, especially for BRCA wild-type patients. This may be a new first-line option for mTNBC. (3) Eribulin may be a promising combination partner for immunotherapy as first-line treatment of mTNBC. Future studies could assess the efficacy based on PD-L1 status to describe the certain population that would benefit the most from the combination of therapy. (4) The major enzyme of eribulin metabolism is cytochrome P450 (CYP) 3A4. As a competitive inhibitor, eribulin might affect the CYP3A4 metabolism of several therapeutic agents and lead to increased toxicity, such as paclitaxel, midazolam, and terfenadine. A clinical study of drug-drug interactions showed that eribulin could be safely co-administered with ketoconazole at a 50% reduction in dose [45]. However, there still lacks sufficient in vivo data. (5) Eribulin-related myelosuppression is reversible, not cumulative, which can be managed by dose delay or reduction, or by the use of granulocyte colony-stimulating factor (G-CSF). G-CSF may be considered for primary prevention in patients who have experienced significant hematologic toxicity in previous chemotherapy regimens [46], particularly in patients with hepatic impairment or severely impaired renal function or elderly patients [47]. (6) The incidence of peripheral neuropathy after treatment with eribulin might be relatively low compared to taxanes and vinorelbine. When eribulin was combined with gemcitabine, peripheral neurotoxicity was significantly lower than that of paclitaxel combined with gemcitabine. Eribulin is likely to replace paclitaxel as a drug combined with gemcitabine to reduce adverse reactions.

4. Novel Targeted Therapeutic Agents

4.1. ADCs

ADCs are novel and highly effective targeted drugs that combine monoclonal antibodies to one or several small cytotoxic drug molecules through linkers. There are three ADCs including sacituzumab govitecan, ladiratuzumab vedotin and trastuzumab deruxtecan, that show obvious clinical efficacy against TNBC. Sacituzumab govitecan was approved as the first ADC by Food and Drug Administration (FDA) and National Medical Products Administration for the treatment of adult patients with mTNBC who have received at least two previous therapies [48]. Trastuzumab deruxtecan was approved by FDA for the treatment of adult patients with unresectable or metastatic HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization (ISH)-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy [49].

Sacituzumab govitecan is an ADC combining a monoclonal humanized antibody targeting Trop-2 as a high ratio of the DNA topoisomerase 1 inhibitor SN-38 [50]. Saci-
tuzumab govitecan can bind to Trop-2 on the surface of tumor cells and enter tumor cells through target-mediated endocytosis [51]. This mechanism may reduce toxic effects in normal tissues that do not express the target, and can both minimize off-target toxicity and maximize the effect of the drug on tumor cells expressing Trop-2. Sacituzumab govitecan showed good efficacy in TNBC patients in both Phase I/II and Phase III clinical trials as a monotherapy with significant improvement of PFS, OS, and ORR (35.5% in sacituzumab govitecan group versus 5% in chemotherapy group), especially in patients with high or medium Trop-2 expression [50,52–54]. The most common adverse events of any grade were neutropenia, diarrhea, nausea, alopecia, fatigue, and anemia. Myelosuppression and diarrhea were more frequent grade 3 adverse events in patients with sacituzumab govitecan than with chemotherapy [53]. Moreover, neutropenia was associated with uridine diphosphate glucuronosyltransferase family 1 member A1 (UGT1A1)*28 homozygosity and the incidence increased with the increase in the copy number [52] (Table 2).

Table 2. Clinical trials of novel targeted therapeutic agents approved for mTNBC.

| Phase     | Intervention                        | Line of Therapy          | Patients | Efficacy                  | Safety (AE ≥ Grade 3)                                                                 |
|-----------|-------------------------------------|---------------------------|----------|---------------------------|--------------------------------------------------------------------------------------|
| Phase 3  | Sacituzumab govitecan vs. single-agent chemotherapy | Second- or later-line mTNBC | 468      | ORR: 35% vs. 5%; OS: 12.1 vs. 6.7 months; PFS: 5.6 vs. 1.7 months | Neutropenia: 51% vs. 33%; leukopenia: 10% vs. 5%; anemia: 8% vs. 5%; febrile neutropenia: 6% vs. 2%; diarrhea: 10% vs. <1% |
| Phase 1/2 | Sacituzumab govitecan               | Third- or later-line mTNBC | 108      | ORR: 33.3%; OS: 13.0 months; PFS: 5.5 months | Neutropenia: 39%; leukopenia: 1%; diarrhea: 13%; vomiting and hypophosphatemia: 10%; |
| Phase 1  | Trastuzumab deruxtecan              | advanced/metastatic HER2-low–expressing breast cancer | 54       | ORR: 37.0%; median duration of Response: 10.4 months | Total: 63.0%; decreases in neutrophil; platelet; WBC counts; anemia; hypokalemia; AST increase; decreased appetite; diarrhea |
| Phase 3  | Trastuzumab deruxtecan vs. the physician’s choice of chemotherapy | Second- or later-line HER2-low metastatic breast cancer | 557      | PFS: 10.1 months vs. 5.4 months; OS: 23.9 months vs. 17.5 months | Total: 52.6% vs. 67.4%; Neutropenia: 13.7% vs. 40.7%; anemia: 8.1% vs. 4.7%; Nausea: 4.6% vs. 0%; fatigue: 7.5% vs. 4.7% |
| Phase 3  | Olaparib vs. single-agent chemotherapy | HER2-negative mBC with gBRCAm | 302      | ORR: 59.9% vs. 28.8%; OS: 19.3 vs. 17.1 months; PFS: 7.0 vs. 4.2 months | Anemia: 36.6% vs. 50.5% |
| Phase 2  | Olaparib                            | First-line TNBC           | 32       | ORR: 56.3% ORR (BRCA mutations vs. not BRCA mutations): 88.9% vs. 11.1% | Fatigue: 3% |
| Phase 2  | Olaparib                            | NR Advanced ovarian carcinoma or TNBC | 91       | NR | Nausea, fatigue, vomiting, decreased appetite |
| Phase 3  | Veliparib + carboplatin + paclitaxel | Third- or later-line Advanced HER2-negative BC with gBRCAm | 513      | ORR: 75.8% vs. 74.1%; OS: 33.5 vs. 28.2 months; PFS: 14.5 vs. 12.6 months | Neutropenia: 81% vs. 84%; anemia: 42% vs. 40%; thrombocytopenia: 40% vs. 28% |
| Phase 3  | Talazoparib vs. single-agent chemotherapy | Second- or later-line Advanced BC with gBRCAm | 431      | ORR: 62.6% vs. 27.2%; PFS: 8.6 vs. 5.6 months | Primary anemia: 55% vs. 38%; nonhematologic: 32% vs. 38% |
| Phase 2  | Talazoparib                          | Third-line Advanced BC with gBRCA m | 84       | ORR (TNBC): 26% | Anemia; thrombocytopenia; neutropenia |

AE: adverse event; mTNBC: metastatic triple-negative breast cancer; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; gBRCAm: germline BRCA-mutated; PARP: polyadenosine diphosphate-ribose polymerase; BC: breast cancer; HER2: human epidermal growth factor receptor 2; NR: not reported.
Unlike sacituzumab govitecan, trastuzumab deruxtecan is a HER2-targeted ADC with a topoisomerase I inhibitor payload, which was initially proved to be effective against HER2-positive breast cancer [64]. However, since a phase 1 study showed promising clinical antitumor activity and a controlled safety profile in HER2-negative breast cancer patients [55], more clinical studies have found significant efficacy of trastuzumab deruxtecan in HER2-low (IHC 1+ vs. IHC 2+/ISH−) mBC with significantly longer PFS and OS than the physician’s choice of chemotherapy (10.1 months versus 5.4 months, 23.9 months versus 17.5 months, respectively) [56]. The most common drug-related adverse events of trastuzumab deruxtecan were nausea, fatigue, thrombocytopenia, decreased appetite, and alopecia; all of these occurred at higher rates than the chemotherapy group and might be positively related to the dosage [55].

From pharmacists’ perspective, there are several points regarding the use of sacituzumab govitecan. (1) Sacituzumab govitecan and trastuzumab deruxtecan can be used as third-line or later treatment for mTNBC and is the preferred treatment for refractory TNBC. However, further studies on the exact efficacy of trastuzumab deruxtecan in mTNBC patients are critical. (2) There are no biomarkers that can clearly predict the efficacy of sacituzumab govitecan. The expression level of Trop-2 may be a biomarker associated with the efficacy of sacituzumab govitecan and high expression of Trop-2 may predict the benefit of this drug [65]. Moreover, gBRCA1/2m status was initially found to be a potential predictive biomarker of response to sacituzumab govitecan in breast cancer [54]. Nectin-4, which is only expressed in TNBC, may also be a new promising prognostic biomarker and target. Efficiency was found to be dependent on both the dose and the nectin-4 tumor expression level in the anti-nectin 4 ADC and (N41mab-vcMMAE) was developed [66]. (3) SN-38 is the cytotoxic component of sacituzumab govitecan, which is a highly potent topoisomerase I inhibitor and metabolite of irinotecan. Some SN-38 is easily converted to lower active forms, such as SN-38 glucuronide (SN-38G), a product of glucuronic acid, which can cause diarrhea by spreading bacterial enzymes through the enterohepatic circulation. Low levels of SN-38G in serum and SN-38/SN-38G in the gut are expected to reduce the risk of severe diarrhea in patients [67]. The concomitant use of drugs that affect the activity of UGT1A1 such as irinotecan should be avoided, because it is involved in the metabolism of SN-38 to SN-38G and may increase the frequency and severity of adverse reactions [68]. (4) When patients first develop grade 4 neutropenia for a minimum 7-day duration or grade 3 febrile neutropenia, a 25% reduction in sacituzumab govitecan dose and administration of G-CSF is recommended in the prescribing information released by the FDA [69]. However, the evidence for prophylactic use of G-CSF is very limited and preliminary prophylactic use is not recommended [70]. (5) Evidence suggests an increased risk of adverse reactions in patients with the UGT1A1*28 variant genotype. The appropriate dose for these patients is unknown. Therefore, it is necessary to explore whether there is a minimum threshold for dose reduction in patients with UGT1A1*28 purex, thereby reducing toxicity [70].

4.2. PARP Inhibitor

PARP is a new target in cancer therapy, which can repair single-strand DNA damage via the base excision pathway. PARP inhibitors can treat cancers with defective homologous recombination DNA repair defects such as BRCA1/2 mutation [71]. Approximately 20% of TNBC patients have a germline defect in BRCA1/2 [72]. Olaparib and talazoparib have been proved to significantly improve the clinical response rate compared to chemotherapy in patients with unselected TNBC with germline BRCA-mutated (gBRCAm) [57–59,62]. However, patients without BRCA mutations had a low response rate in unselected TNBC. Moreover, olaparib was found to be ineffective in patients with wild-type BRCA1/2 mTNBC [60]. Currently, olaparib and talazoparib have been approved by the FDA and European Medicines Agency (EMA) for the treatment of patients with gBRCAm HER2-negative mBC, and veliparib is still in clinical trials [61,73,74]. Talazoparib has higher activity and selectivity than other PARP inhibitors [63], and shows more effectiveness and less toxicity as second-line treatment than capecitabine, gemcitabine and
vinorelbine [62,75]. Olaparib and talazoparib may cause severe hematologic toxicities such as myelodysplastic syndrome and acute myeloid leukemia, which mostly occur within the first three months. However, there are differences in the rates of adverse events between the two drugs, especially higher rates of nausea and vomiting in patients treated with olaparib and higher rates of alopecia and anemia in patients treated with talazoparib [59,62]. Nausea and vomiting have been clearly demonstrated to be the most common adverse effects of PARP inhibitors. The National Comprehensive Cancer Network concludes that olaparib carries a moderate to high risk of vomiting. Moreover, olaparib has significantly stronger rare and severe hematological toxicity than other PARP inhibitors, including myelodysplastic syndrome, bone marrow failure and acute myeloid leukemia, warranting caution in clinical drug therapy [76]. The details are shown in Table 2.

PARP inhibitors resistance has been proved to be a thorny problem [77]. Prior acquired resistance to platinum agents may promote PARP inhibitors resistance. Currently, the main way to overcome resistance to PARP inhibitors is in combination with other drugs, such as immunotherapy drugs and chemotherapeutic drugs [78]. Olaparib plus carboplatin or durvalumab have been proved to be a safe and effective option by increasing OS in TNBC [78,79]. Moreover, HSP90 inhibitor onalespib has also been proved to be a potential partner of olaparib, and exhibited antitumor activity against BRCA1-mutated patient-derived xenograft models with acquired PARP inhibitors’ resistance and the models with retinoblastoma-pathway alterations in preclinical and phase 1 studies [80]. Therefore, finding the best combination of PARP inhibitors and reducing toxicity is a problem to be solved.

Based on these findings, the following points are of concern from pharmacists’ view. (1) In mTNBC patients with gBRCAm and PD-L1 negative, PARP inhibitors may be first-line treatment options recommended by the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines [6,7]. However, there is insufficient evidence to determine the optimal sequencing of PARP inhibitors with other regimens. This should be considered based on disease burden, prior treatment response, drug toxicity, and PD-L1 status. (2) gBRCAm may be an effective biomarker of PARP inhibitors, and genetic testing for pathogenic variants in BRCA1/2 is recommended for all TNBC patients, regardless of age, family history or BC subtype [6]. (3) PARP inhibitors are easy to use orally and show good compliance for most patients. Nonetheless, it may interact with a variety of drugs due to CYP450 enzyme inhibition or induction, such as phenytoin, carbamazepine, and ciprofloxacin, which may reduce PARP inhibitor efficacy or be associated with serious adverse drug reactions [81]. Prescribing information issued by the FDA recommends that olaparib should be avoided in combination with CYP3A inhibitors and inducers. If this cannot be avoided, the dose should be reduced [82]. Evaluation of the patient for all concomitant medications and guidance on specific foods and medications that the patient should avoid is an important measure prior to the use of PARP inhibitors. (4) In addition, for oral drugs, some patients may use drugs incorrectly, especially those with poor compliance. They should be instructed to use drugs correctly, including usage and dosage, and advised of common adverse reactions and treatment measures, and replacement methods for missed drugs. (5) It is also important to note that the order of administration of combination therapy may affect the efficacy. There is evidence that when olaparib is combined with carboplatin, pre-exposure of carboplatin can lead to intracellular accumulation of olaparib and reduce bioavailability [79], so olaparib should be administered first. (6) Due to the high risk of vomiting, 5-hydroxytryptamine 3 receptor antagonists such as ondansetron, dolasetron and granisetron should be used to prevent nausea and vomiting [62]. (7) In the first three months of treatment, patients’ complete blood counts should be closely monitored. If a patient with hematologic toxicity does not recover within 28 days or continues to lose cells after dose adjustment, further investigation must be performed, and whether to discontinue the PARP inhibitor must be considered [83].
5. Immune Checkpoint Inhibitors (ICIs)

TNBC is more likely to benefit from ICIs therapy than other breast cancer subtypes [84] due to a large number of tumor-infiltrating lymphocytes (TIL), high level of PD-L1 expression and greater number of nonsynonymous mutations, which can generate tumor-specific neoantigens and activate specific T cells, so as to produce antitumor immune responses [85]. Optimal responses to immunotherapeutic drugs depend on appropriate priming of T cells through antigen processing and presentation and co-stimulation of activated dendritic cells. A PD-L1-positive tumor, first-line immunotherapy, high TIL level, non-liver metastasis, and high CD8+ T-cell infiltrating level were found to predict high ORR in ICIs treatment [86]. Compared with standard chemotherapy, ICIs therapy demonstrated more favorable responses in the first-line setting [87–91]. We have summarized the data from the clinical trials of ICIs treatment for mTNBC in Table 3.

Table 3. Clinical trials of ICIs approved for mTNBC.

| Phase | Intervention | Line of Therapy | Patients | N | Efficacy | Safety (AE ≥ Grade 3) |
|-------|--------------|-----------------|----------|---|----------|----------------------|
| Phase 3 trial [91] | Pembrolizumab vs. chemotherapy | Second- or third-line mTNBC | 622 | (1) CPS ≥ 10: ORR: 18%; OS: 12.7 vs. 11.6 months; (2) CPS ≥ 1: ORR: 12%; OS: 10.7 vs. 10.2 months | Total: 68% vs. 67% immune-mediated AE: 5% vs. 0% |
| Phase 3 trial [92] | Pembrolizumab + chemotherapy vs. chemotherapy | First-line mTNBC | 847 | (1) CPS ≥ 10: PFS: 9.7 vs. 5.6 months; (2) CPS ≥ 1: PFS: 7.6 vs. 5.6 months | Total: 68% vs. 67% immune-mediated AE: 5% vs. 0% |
| Phase 2 trial [87] | Pembrolizumab | Second- or later-line (Cohort A) mTNBC | 170 | (1) Total: ORR: 5.3%; DCR: 7.6%; OS: 9.0 months; (2) PD-L1+: ORR: 5.7%; DCR: 9.5% | Total: 68% vs. 67% immune-mediated AE: 5% vs. 0% |
| Phase 2 trial [93] | Pembrolizumab | First-line (Cohort B) mTNBC | 84 | ORR: 21.4%; DCR: 23.8%; OS: 18.0 months; PFS: 2.1 months | Total: 9.5%; immune-mediated AE: rash |
| Phase 3 trial [94] | Atezolizumab + nab-paclitaxel vs. nab-paclitaxel | First-line mTNBC | 902 | (1) Total: ORR: 21.0 vs. 18.7 months; (2) PD-L1+: ORR: 25.0 vs. 18.0 months | Neutropenia: 8% vs. 8%; peripheral neuropathy: 6% vs. 3%; decreased neutrophil count: 5% vs. 4%; fatigue: 4% vs. 3% |
| Phase 3 trial [95] | Atezolizumab + paclitaxel vs. paclitaxel | First-line PD-L1-positive mTNBC | 651 | ORR: 63% vs. 55%; OS: 22.1 vs. 28.3 months; PFS: 6.0 vs. 5.7 months | Total: 53% vs. 46% |
| Phase 2 trial [96] | Pembrolizumab + radiotherapy | NR mTNBC | 17 | ORR: 17.6%; PFS: 2.6 months; OS: 8.25 months | Fatigue; lymphopenia; infection |
| Phase 2 trial [97] | Niraparib + pembrolizumab | NR mTNBC | 55 | ORR: 21%; PD-L1+: 32%; PFS: 2.3 months | Anemia: 18%; thrombocytopenia: 15%; fatigue: 7% |
| Phase 2 trial [98] | Pembrolizumab plus enobosarm | AR-positive mTNBC | 16 | ORR: 13%; OS: 25.5 months; PFS: 2.6 months | Musculoskeletal ache: 6%; dry skin: 6%; diarrhea: 6% |

AE: adverse event; HR: hazard ratio; mTNBC: metastatic triple-negative breast cancer; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; AR: androgen receptor; PD-L1: programmed cell death 1 ligand 1; DCR: disease control rate; CPS: combined positive score; NR: not reported.

Atezolizumab has been shown to be active and safe in a small group of patients with TNBC. Atezolizumab combined with nab-paclitaxel could significantly improve the median PFS and OS in untreated mTNBC patients, especially in PD-L1 positive patients [94,99,100]. This combination regimen has been approved for advanced and metastatic TNBC patients with positive PD-L1 (combined positive score, CPS ≥ 10) by EMA [101]. However, ate-
zolizumab combined with paclitaxel has not shown improved PFS and OS in mTNBC patients, indicating that paclitaxel should not replace nab-paclitaxel when atezolizumab is combined with chemotherapy [95]. Pembrolizumab monotherapy showed good antitumor activity and efficacy may be correlated with the treatment line, with the ORR for first-line therapy significantly higher than second- or later-lines therapy (21.4%, 18% and 5.7%, respectively) [87,91,93]. Compared to pembrolizumab monotherapy, pembrolizumab plus chemotherapy showed more significant improvement in PFS among patients with mTNBC with a CPS of 10 or more, and provided consistent benefit irrespective of the chemotherapy partner in subgroups. With PD-L1 negative or CPS < 1, there was no significant clinical benefit compared with placebo plus chemotherapy [92]. Pembrolizumab plus chemotherapy has also been approved by the FDA for the treatment of locally recurrent or mTNBC patients with PD-L1 positive [102]. Nab-paclitaxel might enhance antitumor activity and has promising activity when combined with pembrolizumab as the first-line treatment of mTNBC patients [103]. In addition, the combination of pembrolizumab and eribulin was generally well tolerated and had greater antitumor activity than either the drug alone for patients with mTNBC [41]. Immune-related adverse events (irAEs) caused by inhibition of PD-1/PD-L1 inhibitors are common both in clinical trials and clinical applications with varied reactions among individuals, including immune-related skin adverse reactions, gastrointestinal adverse events, hepatitis, pneumonia, and thyroid dysfunction [104]. Nevertheless, the majority of toxicities are low in severity. Postponing and stopping ICIs treatment can alleviate the adverse reactions [104].

The following points regarding ICIs treatment of mTNBC are of interest to pharmacists. (1) The combination of pembrolizumab/atezolizumab and nab-paclitaxel may be a first-line treatment strategy for mTNBC patients with PD-L1 positive tumors. (2) Pembrolizumab plus eribulin may be a promising option with good efficacy and manageable safety for patients with mTNBC. (3) In patients with mTNBC, a comprehensive assessment of biomarkers that can predict response to ICIs is critical. In detail, PD-L1 expression levels may be positively correlated with efficacy, but it is not sufficient to assess this alone [105]. Several biomarkers may also predict the efficacy of ICIs, such as PD-L1 expression, the number of TIL, number of CD4+ T cells, tumor mutational burden (TMB) status, microsatellite instability (MSI) status, mismatch-repair deficiency (dMMR), age, etc. [106]. Tumor cells with high TMB can produce more tumor-associated antigens that can be recognized by T lymphocytes to activate an immune attack. Anti-PD-1 treatment can make T cell response more effective, so tumors with high TMB may be more sensitive to anti-PD-1 treatment. In addition, solid tumors in MSI-H/dMMR are usually immunogenic and have extensive T-cell infiltration, which makes them highly responsive to ICIs. CD8+ T cells are effector cells that directly kill tumor cells in tumor microenvironment, but are inhibited by the PD-1/PD-L1 pathway [107]. Therefore, the number of TIL can be used as a predictor to assess the immune responses. (4) Paclitaxel may not be substituted for the nab-paclitaxel as a combination of atezolizumab for the treatment of mTNBC. The reasons for the different results may be the difference in the clinical activity between paclitaxel and nab-paclitaxel, the heterogeneity of TNBC, and previous treatment [108]. Compared to paclitaxel, nab-paclitaxel, which uses albumin nanoparticles as a carrier is more targeted to tumors. At the same time, nab-paclitaxel can be directly dissolved in normal saline, avoiding the severe allergic side effects caused by traditional paclitaxel injection containing a large amount of surfactant [109], and there is no need to use glucocorticoid or antihistamine drugs for anti-allergic pretreatment of patients in clinical practice. Therefore, it should be considered that the concomitant use of paclitaxel with steroids may reduce immunosuppressant efficacy. (5) Corticosteroid therapy is usually the first-line treatment against irAEs, as recommended by the ASCO guideline. Grade 3 toxicities generally warrant suspension of ICIs and the initiation of high-dose corticosteroids [104]. Discontinuation of ICIs is recommended at the onset of grade 4 toxicity, except for endocrine disorders that have been controlled by hormone replacement [104]. However, due to the immunosuppressive effect and more adverse reactions such as infections, the use of corticosteroids needs careful management.
The initial treatment with 1 mg/kg daily methylprednisolone could provide similar efficacy with reduced risk of steroid-related complications when compared with higher-dose regimens [110]. Therefore, low-dose corticosteroids, close follow-up, and regular inspection are important measures to reduce irAEs [111]. (6) Early identification and continuous monitoring of irAEs is critical. Exploring biomarkers to predict and early identify irAEs risk is an urgent issue. Clinically, circulating blood cell counts are a biomarker that is accessible in current clinical practice. Other biomarkers such as cytokines, autoantibodies, serum proteins, intestinal microbiota, microRNA and gene profiling need more research before they can be adopted in practice [112]. (7) Due to the non-specific characteristics of irAEs symptoms, for many patients and medical staff, they are difficult to detect and recognize. Pharmacists can provide consulting services and rigorous pre-education to patients and medical staff can promote the understanding, identification and management of irAEs, as well as reduce the possibility of discontinuation of treatment due to irAEs.

6. Conclusions

Chemotherapy has always been the backbone therapy for mTNBC. The development of new chemotherapy drugs, targeted drugs and immunotherapy drugs provides more options for the treatment of mTNBC. Utidelone and eribulin provide an effective treatment option for mTNBC patients who are resistant to chemotherapy such as anthracyclines and taxanes. Targeted therapeutics ADCs and PARP inhibitors have the advantages of high selectivity, high destruction and controllable toxicity. In particular, ICI s will occupy a place in the first-line treatment of mTNBC. The study of optimal combined therapy strategies will be the focus of the treatment of mTNBC in the future. As the same time, due to the heterogeneity of mTNBC, the challenges are to undertake studies on more selected patient populations and to identify reliable biomarkers to predict treatment response. Pharmacists can play an important role because these drugs are still in their infancy in the treatment of TNBC. They can ensure the effectiveness, safety, economy and suitability of drugs in clinical application through drug therapy management, pharmacoeconomic evaluation, drug application evaluation and toxicity management research.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11206021/s1. The details of the literature search strategies.

Author Contributions: S.L. and L.H. prepared the manuscript and wrote the draft together; C.B. prepared the figures and tables. L.H. and J.-F.W. revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Garrido-Castro, A.C.; Lin, N.U.; Polyak, K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019, 9, 176–198. [CrossRef]
2. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434. [CrossRef]
3. Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Clinical features and patterns of recurrence. Nat. Rev. Clin. Oncol. 2016, 13, 674–690. [CrossRef]
4. Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S.C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020, 22, 61. [CrossRef]
5. Jiang, Y.Z.; Ma, D.; Suo, C.; Shi, J.; Xue, M.; Hu, X.; Xiao, Y.; Yu, K.D.; Liu, Y.R.; Yu, Y.; et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 2019, 35, 428–440. [CrossRef]
6. Gennari, A.; Andre, F.; Barrios, C.H.; Cortes, J.; de Azambuja, E.; DeMichele, A.; Dent, R.; Fenlon, D.; Gligorov, J.; Hurvitz, S.A.; et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann. Oncol.* 2021, 32, 1475–1495. [CrossRef]

7. Moy, B.; Rumble, R.B.; Come, S.E.; Davidson, N.E.; Di Leo, A.; Gralow, J.R.; Hortobagyi, G.N.; Yee, D.; Smith, I.E.; Chavez-MacGregor, M.; et al. Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *J. Clin. Oncol.* 2021, 39, 3938–3958. [CrossRef]

8. Nandini, D.; Jennifer, A.; Pradip, D. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. *Pharmaceuticals* 2021, 14, 455. [CrossRef]

9. Hwang, S.Y.; Park, S.; Kwon, Y. Recent therapeutic trends and promising targets in triple negative breast cancer. *Pharmacol. Ther.* 2019, 199, 30–57. [CrossRef]

10. Lu, P.; Santa-Maria, C.A.; Ballinger, T.J.; Sheng, J.Y. Landmark trials in the medical oncology management of metastatic breast cancer. *Semin. Oncol.* 2021, 48, 246–258. [CrossRef]

11. Nedeljkovic, M.; Damjanovic, A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. *Cells* 2019, 8, 957. [CrossRef]

12. Caparica, R.; Lamberti, M.; de Azambuja, E. How I treat metastatic triple-negative breast cancer. *ESMO Open* 2019, 4, e000504. [CrossRef]

13. Zhu, Y.; Hu, Y.; Tang, C.; Guan, X.; Zhang, W. Platinum-based systematic therapy in triple-negative breast cancer. *Biochim. Biophys. Acta Rev. Cancer* 2022, 1877, 186678. [CrossRef]

14. Yu, K.D.; Ye, F.G.; He, M.; Fan, L.; Ma, D.; Mo, M.; Wu, J.; Liu, G.Y.; Di, G.H.; Zeng, X.H.; et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020, 6, 1390–1396. [CrossRef]

15. Poggio, F.; Buzzzone, M.; Ceppi, M.; Ponde, N.F.; La Valle, G.; Del Mastro, L.; de Azambuja, E.; Lamberti, M. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. *Ann. Oncol.* 2018, 29, 1497–1508. [CrossRef]

16. Fan, Y.; Xu, B.H.; Yuan, P.; Ma, F.; Wang, J.Y.; Ding, X.Y.; Zhang, P.; Li, Q.; Cai, R.G. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. *Ann. Oncol.* 2013, 24, 1219–1225. [CrossRef]

17. Hu, X.C.; Zhang, J.; Xu, B.H.; Cai, L.; Ragaz, J.; Wang, Z.H.; Wang, B.Y.; Teng, Y.E.; Tong, Z.S.; Pan, Y.Y.; et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): A randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2015, 16, 436–446. [CrossRef]

18. Zhang, J.; Wang, Z.H.; Hu, X.; Wang, B.; Wang, L.; Yang, W.; Liu, Y.; Liu, G.Y.; Di, G.H.; Hu, Z.I.; et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative. *Int. J. Cancer* 2015, 136, 204–211. [CrossRef]

19. Priyanka, S.; Eve, R.; William, E.B.; Julie, G.; Shannon, L.H.P.; Carey, K.A.; Lori, J.G.; Ursa, A.B.G.; Thu-Tam, H.; Christopher, S.S.; et al. Results of a phase II randomized trial of cisplatin + veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). *J. Clin. Oncol.* 2020, 38, 1001. [CrossRef]

20. Fumoleau, P.; Coudert, B.; Isambert, N.; Ferrant, E. Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. *Ann. Oncol.* 2007, 19, v9–v15. [CrossRef]

21. Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovsky, J.V.; de Mendoza, F.H.; et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. *J. Clin. Oncol.* 2015, 33, 1390–1396. [CrossRef]

22. MacGregor, M.; et al. Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *J. Clin. Oncol.* 2021, 39, 3938–3958. [CrossRef]

23. Zhang, P.; Sun, T.; Zhang, Q.; Yuan, Z.; Jiang, Z.; Wang, X.J.; Cui, S.; Teng, Y.; Hu, X.C.; Yang, J.; et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: A multicentre, open-label, superiority, phase 3, randomised controlled trial. *Lancet Oncol.* 2017, 18, 371–383. [CrossRef]

24. Xu, B.; Sun, T.; Zhang, Q.; Zhang, P.; Yuan, Z.; Jiang, Z.; Wang, X.; Cui, S.; Teng, Y.; Hu, X.C.; et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: Final analysis of overall survival in a phase III randomised controlled trial. *Ann. Oncol.* 2021, 32, 218–228. [CrossRef]

25. Zhang, P.; Sun, M.Y.; Qiu, R.G.; Tang, L.; Dou, G.; Xu, B. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. *Cancer Chemother. Pharmacol.* 2011, 68, 971–978. [CrossRef]

26. Zhang, P.; Tong, Z.; Tian, F.; Wang, Y.; Yang, J.; Li, W.; Di, L.; Liu, W.; Tang, L.; Qiu, R.; et al. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. *J. Hematol. Oncol.* 2016, 9, 016–0297. [CrossRef]

27. Xu, J.; Wang, Y.; Jiang, C.; Cao, H.; Jiang, J.; Xu, B.; Sun, T. Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial. *Front. Oncol.* 2020, 10, 524223. [CrossRef]
28. Bao, T.; Seidman, A.D.; Piulson, L.; Vertosick, E.; Chen, X.; Vickers, A.J.; Blinder, V.S.; Zhi, W.I.; Li, Q.; Vahdat, L.T.; et al. A phase II A trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. *Eur. J. Cancer* **2018**, *101*, 12–19. [CrossRef]

29. Müller, J.; Weiler, M.; Schneeweiss, A.; Haag, G.M.; Steindorf, K.; Wick, W.; Wiskenmann, J. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: A randomised-controlled trial. *Br. J. Cancer* **2021**, *125*, 955–965. [CrossRef]

30. Liao, M.; Jiang, Q.; Hu, H.; Han, J.; She, L.; Yao, L.; Ding, D.; Huang, J. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. *J. Med. Econ.* **2019**, *22*, 584–592. [CrossRef]

31. Yonemori, K.; Shimomura, A.; Yasojima, H.; Masuda, N.; Aogi, K.; Takahashi, M.; Naito, Y.; Shimizu, S.; Nakamura, R.; Hashimoto, J.; et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. *Eur. J. Cancer* **2019**, *109*, 84–91. [CrossRef] [PubMed]

32. Cortes, J.; O'Shaughnessy, J.; Loesch, D.; Blum, J.L.; Vahdat, L.T.; Petراكova, K.; Chollet, P.; Manikas, A.; Diéras, V.; Delozier, T.; et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. *Lancet* **2011**, *377*, 914–923. [CrossRef]

33. Yuan, P.; Hu, X.; Sun, T.; Li, W.; Zhang, Q.; Cui, S.; Cheng, Y.; Ouyang, Q.; Wang, X.; Chen, Z.; et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. *Eur. J. Cancer* **2019**, *112*, 57–65. [CrossRef] [PubMed]

34. Kaufman, P.A.; Awada, A.; Twelves, C.; Yelle, L.; Perez, E.A.; Velikova, G.; Olivo, M.S.; He, Y.; Dutcans, C.E.; Cortes, J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J. Clin. Oncol.* **2015**, *33*, 594–601. [CrossRef]

35. Pellegrino, B.; Cavanna, L.; Boggiani, D.; Zamagni, C.; Frassoldati, A.; Schirone, A.; Caldara, A.; Rocca, A.; Gori, S.; Piacentini, F.; et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple-negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). *ESMO Open* **2021**, *6*, 100019.

36. De Angelis, C.; Bruzzese, D.; Bernardo, A.; Baldini, E.; Leo, L.; Fabi, A.; Gamucci, T.; De Placido, P.; Poggio, F.; Russo, S.; et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: A multicenter, phase II, single arm trial (GIM11-BERGI). *ESMO Open* **2021**, *6*, 100054. [CrossRef]

37. Hayashida, T.; Jinno, H.; Mori, K.; Sato, H.; Matsui, A.; Sakurai, T.; Hattori, H.; Takayama, S.; Wada, M.; Takahashi, M.; et al. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial. *BMC Cancer* **2018**, *18*, 701. [CrossRef]

38. Ortega, V.; Anton, A.; Garau, I.; Afonso, N.; Calvo, L.; Fernandez, Y.; Martinez-Garcia, M.; Blanco, E.; Zamora, P.; Garcia, M.; et al. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients with Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. *Clin. Breast Cancer* **2019**, *19*, 105–112. [CrossRef]

39. Liu, J.; Wang, Y.; Tian, Z.; Lin, Y.; Li, H.; Zhu, Z.; Liu, Q.; Su, S.; Zeng, Y.; Jia, W.; et al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. *Nat. Commun.* **2012**, *13*, 3011. [CrossRef]

40. Park, Y.H.; Im, S.A.; Kim, S.B.; Sohn, J.H.; Lee, K.S.; Chae, Y.S.; Lee, K.H.; Kim, J.H.; Im, Y.H.; Kim, J.Y.; et al. Randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. *Eur. J. Cancer* **2017**, *86*, 385–393. [CrossRef]

41. Tolaney, S.M.; Kalinsky, K.; Takahashi, M.; Masuda, N.; Aogi, K.; Takahashi, M.; Naito, Y.; Shimizu, S.; Nakamura, R.; Hashimoto, J.; et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. *Eur. J. Cancer* **2019**, *109*, 84–91. [CrossRef] [PubMed]

42. Alday, P.H.; Correa, J.J. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. *Biochemistry* **2009**, *48*, 7927–7938. [CrossRef] [PubMed]

43. Jain, S.; Vahdat, L.T. Eribulin mesylate. *Clin. Cancer Res.* **2011**, *17*, 6615–6622. [CrossRef] [PubMed]

44. Pivot, X.B.; Marmé, F.; Koenigsberg, R.; Guo, M.; Berrak, E.; Wolfer, A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. *Ann. Oncol. Adv. Access* **2016**, *27*, 1525–1531. [CrossRef] [PubMed]

45. Deviere, L.A.; Mergui-Roelvink, M.; Wanders, J.; Jenner, A.; Edwards, G.; Reyderman, L.; Copalu, W.; Peng, F.; Marchetti, S.; Beijnen, J.H.; et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. *Investig. New Drugs* **2013**, *31*, 381–389. [CrossRef]

46. Ro, J.; Cheng, F.T.; Sriuranpong, V.; Villalon, A.; Smruti, B.K.; Tsang, J.; Yap, Y.S.; Asian Working Group for Eribulin Clinical Guide. Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide. *J. Breast Cancer* **2016**, *19*, 8–17. [CrossRef]

47. Deviere, L.A.; Witteveen, P.O.; Marchetti, S.; Mergui-Roelvink, M.; Reyderman, L.; Wanders, J.; Jenner, A.; Edwards, G.; Beijnen, J.H.; Voest, E.E.; et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer Chemother. Pharmacol.* **2012**, *70*, 823–832. [CrossRef]

48. Syed, Y.Y. Sacituzumab Govitecan: First Approval. *Drugs* **2020**, *80*, 1019–1025. [CrossRef]
65. Vranic, S.; Gatalica, Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and...

57. Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib...

55. Modi, S.; Park, H.; Murthy, R.K.; Iwata, H.; Tamura, K.; Tsurutani, J.; Moreno-Aspitia, A.; Doi, T.; Sagara, Y.; Redfern, C.;...

52. Bardia, A.; Mayer, I.A.; Vahdat, L.T.; Tolaney, S.M.; Isakoff, S.J.; Diamond, J.R.; O'Shaughnessy, J.; Santin, A.D.; Abramson, V.G.; et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. *N. Engl. J. Med.* 2019, 380, 741–751. [CrossRef] [PubMed]

53. Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnick, A.B.; et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N. Engl. J. Med.* 2021, 384, 1529–1541. [CrossRef] [PubMed]

54. Bardia, A.; Tolaney, S.M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnick, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. *Ann. Oncol.* 2021, 32, 1148–1156. [CrossRef]

55. Modi, S.; Park, H.; Murthy, R.K.; Iwata, H.; Tamura, K.; Tsurutani, J.; Moreno-Aspitia, A.; Doi, T.; Sagara, Y.; Redfern, C.; et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer. *Results from a Phase Ib Study*. *J. Clin. Oncol.* 2020, 38, 1887–1896. [CrossRef] [PubMed]

56. Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N. Engl. J. Med.* 2017, 377, 523–533. [CrossRef]

57. Modé, M.; Tung, N.; Conte, P.; Im, S.-A.; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A.; et al. OlympiAD final overall survival and tolerability results. *Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative tumours*. *Med. Oncol.* 2019, 30, 558–566.

58. Eikesdal, H.P.; Yndestad, S.; Elzawahry, A.; Llop-Guevara, A.; Gilje, B.; Blix, E.S.; Espelid, H.; Lundgren, S.; Geisler, J.; Vagstad, G.; et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Ann. Oncol.* 2021, 32, 240–249. [CrossRef]

59. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

60. Eikesdal, H.P.; Yndestad, S.; Elzawahry, A.; Llop-Guevara, A.; Gilje, B.; Blix, E.S.; Espelid, H.; Lundgren, S.; Geisler, J.; Vagstad, G.; et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Ann. Oncol.* 2021, 32, 240–249. [CrossRef]

61. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

62. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

63. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

64. Eikesdal, H.P.; Yndestad, S.; Elzawahry, A.; Llop-Guevara, A.; Gilje, B.; Blix, E.S.; Espelid, H.; Lundgren, S.; Geisler, J.; Vagstad, G.; et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Ann. Oncol.* 2021, 32, 240–249. [CrossRef]

65. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

66. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

67. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

68. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

69. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

70. Fingerhut, A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol.* 2011, 12, 852–861. [CrossRef]

71. Lyons, T.G. Targeted Therapies for Triple-Negative Breast Cancer. *Curr. Treat. Options Oncol.* 2019, 20, 82. [CrossRef]
72. Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017, 317, 2402–2416. [CrossRef]

73. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-olaparib-gbrcam-her2-negative-metastatic-breast-cancer (accessed on 12 January 2018).

74. Available online: https://www.fda.gov/drugs/approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-metastatic-breast-cancer (accessed on 16 October 2018).

75. Hurvitz, S.A.; Queck, R.G.W.; Turner, N.C.; Telli, M.L.; Rugo, H.S.; Mailliez, A.; Ettl, J.; Grischke, E.M.; Mina, L.A.; Balmaña, J.; et al. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: Patient-reported outcomes from the ABRAZO phase 2 trial. Eur. J. Cancer 2018, 164, 160–168. [CrossRef] [PubMed]

76. Tian, X.; Chen, L.; Gai, D.; He, S.; Jiang, X.; Zhang, N. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Front. Pharmacol. 2022, 13, 851246. [CrossRef] [PubMed]

77. Rottenberg, S.; Jaspers, J.E.; Kersbergen, A.; van der Burg, E.; Nygren, A.O.; Zander, S.A.; Derksen, P.W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 2008, 105, 17079–17084. [CrossRef] [PubMed]

78. Domchek, S.M.; Postel-Vinay, S.; Im, S.A.; Park, Y.H.; Delord, J.P.; Italiano, A.; Alexandre, J.; You, B.; Bastian, S.; Krebs, M.G.; et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020, 21, 1155–1164. [CrossRef]

79. Lee, J.M.; Peer, C.J.; Yu, M.; Amable, L.; Gordon, N.; Annunziata, C.M.; Houston, N.; Goey, A.K.; Sissung, T.M.; Parker, B.; et al. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/ib Study of Olaparib Tablets and Carboplatin in Women’s Cancer. Clin. Cancer Res. 2017, 23, 1397–1406. [CrossRef]

80. Konstantinopoulos, P.A.; Cheng, S.C.; Supko, J.G.; Polak, M.; Wahner-Hendrickson, A.E.; Ivy, S.P.; Bowes, B.; Sawyer, H.; Basada, P.; Hayes, M.; et al. Combined PARP and HSP90 inhibition: Preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br. J. Cancer 2022, 126, 1027–1036. [CrossRef]

81. Zhao, D.; Long, X.; Wang, J. Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors. Oncol. Rep. 2022, 47, 23. [CrossRef]

82. LYNPARZA® (Olaparib) Tablets, for Oral Use. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf (accessed on 12 January 2018).

83. LYNPARZA® (Olaparib) Tablets, for Oral Use. Available online: https://www.fda.gov/drugs/approvals-and-databases/fda-disco-olaparib-gbrcam-her2-negative-metastatic-breast-cancer (accessed on 16 October 2018).

84. Keenan, T.E.; Tolaney, S.M. Role of Immunotherapy in Triple-Negative Breast Cancer. J. Natl. Compr. Cancer Netw. 2020, 18, 479–489. [CrossRef]

85. Kwapisz, D.; Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol. Immunother. 2021, 70, 607–617. [CrossRef]

86. Zou, Y.; Zou, X.; Zheng, S.; Tang, H.; Zhang, L.; Liu, P.; Xie, X. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis. Ther. Adv. Med. Oncol. 2020, 12, 1758835920940928. [CrossRef] [PubMed]

87. Adams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; IWata, H.; Campone, M.; Nanda, R.; et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann. Oncol. 2020, 30, 397–404. [CrossRef]

88. Emens, L.A.; Cruz, C.; Eder, J.P.; Braiteh, F.; Chung, C.; Tolaney, S.M.; Kuter, I.; Nanda, R.; Cassier, P.A.; Delord, J.P.; et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019, 5, 74–82. [CrossRef]

89. Dirix, L.Y.; Takacs, I.; Jerusalem, G.; Nikolainkos, P.; Arkenau, H.T.; Forero-Torres, A.; Bocci, R.; Lippman, M.E.; Somer, R.; Smakal, M.; et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 2018, 167, 671–686. [CrossRef]

90. Nanda, R.; Chow, L.Q.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Aktan, G.; Cheng, J.D.; et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J. Clin. Oncol. 2016, 34, 2460–2467. [CrossRef]

91. Winer, E.P.; Lipatov, O.; Im, S.A.; Goncalves, A.; Muñoz-Couselo, E.; Lee, K.S.; Schmid, P.; Tomura, K.; Testa, L.; Wittel, I.; et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 499–511. [CrossRef]

92. Cortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020, 396, 1817–1828. [CrossRef]
93. Adams, S.; Loi, S.; Toppmeyer, D.; Cescon, D.W.; De Laurentiis, M.; Nanda, R.; Winer, E.P.; Mukai, H.; Tamura, K.; Armstrong, A.; et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. *Ann. Oncol.* 2019, 30, 405–411. [CrossRef]

94. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N. Engl. J. Med.* 2018, 379, 2108–2121. [CrossRef]

95. Miles, D.; Gilgrov, J.; Andre, F.; Cameron, D.; Schneeweiss, A.; Barrios, C.; Xu, B.; Wardley, A.; Kaen, D.; Andrade, L.; et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann. Oncol.* 2021, 32, 994–1004. [CrossRef]

96. Ho, A.Y.; Barker, C.A.; Arnold, B.B.; Powell, S.N.; Hu, Z.I.; Gucalp, A.; Lebron-Zapata, L.; Wen, H.Y.; Kallman, C.; D’Agnolo, A.; et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. *Cancer* 2020, 126, 850–860. [CrossRef]

97. Vinayak, S.; Tolaney, S.M.; Schwartzberg, L.S.; Mita, M.; McCann, G.; Tan, A.R.; Wahner-Hendrickson, A.E.; Forero, A.; Anders, C.; Wulf, G.M.; et al. Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. *JAMA Oncol.* 2019, 5, 1132–1140. [CrossRef]

98. Yuan, Y.; Lee, J.S.; Yost, S.E.; Frankel, P.H.; Ruel, C.; Egelston, C.A.; Guo, W.; Gillece, J.D.; Folkerts, M.; Reining, L.; et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. *Oncologist* 2021, 26, 24. [CrossRef]

99. Schmid, P.; Rugo, H.S.; Adams, S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Henschel, V.; Molinero, L.; Chui, S.Y.; et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2020, 21, 44–59. [CrossRef]

100. Adams, S.; Diamond, J.R.; Hamilton, E.; Pohlmann, P.R.; Tolaney, S.M.; Chang, C.W.; Zhang, W.; Iizuka, K.; Foster, P.G.; Molinero, L.; et al. Atezolizumab Plus Nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer with 2-Year Survival Follow-up: A Phase 1b Clinical Trial. *JAMA Oncol.* 2019, 5, 334–342. [CrossRef]

101. Narayan, P.; Wahby, S.; Gao, J.J.; Amiri-Kordestani, L.; Ibrahim, A.; Bloomquist, E.; Tang, S.; Xu, Y.; Liu, J.; Fu, W.; et al. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. *Clin. Cancer Res.* 2020, 26, 2284–2289. [CrossRef]

102. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple (accessed on 13 November 2020).

103. Schmid, P.; Salgado, R.; Park, Y.H.; Munoz-Couselo, E.; Kim, S.B.; Sohn, J.; Im, S.A.; Foukakis, T.; Kuemmel, S.; Dent, R.; et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. *Ann. Oncol.* 2020, 31, 569–581. [CrossRef]

104. Schneider, B.J.; Naidoo, J.; Santomasso, B.D.; Lacchetti, C.; Adkins, S.; Anadkat, M.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy ASCO Guideline Update. *J. Clin. Oncol.* 2021, 39, 4073–4126. [CrossRef]

105. Doroshow, D.B.; Bhalla, S.; Beasley, M.B.; Sholl, L.M.; Kerr, K.M.; Gnjatic, S.; Wistuba, I.I.; Rimm, D.L.; Tsao, M.S.; Hirsch, F.R. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. *Nat. Rev. Clin. Oncol.* 2021, 18, 345–362. [CrossRef]

106. Qu, J.; Jiang, M.; Wang, L.; Zhao, D.; Qin, K.; Wang, Y.; Tao, J.; Zhang, X. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. *Biomed. Pharmacother.* 2022, 127, 109996. [CrossRef]

107. Miller, B.C.; Sen, D.R.; Al Abosy, R.; Bi, K.; Virkud, Y.V.; LaFleur, M.W.; Yates, K.B.; Lako, A.; Felt, K.; Naik, G.S.; et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat. Immunol.* 2019, 20, 326–336. [CrossRef] [PubMed]

108. Franzoi, M.A.; de Azambuja, E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials—How to explain different results? *ESMO Open* 2020, 5, e001112. [CrossRef] [PubMed]

109. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clin. Cancer Res.* 2006, 12, 1317–1324. [CrossRef] [PubMed]

110. Li, M.; Wong, D.; Vogel, A.S.; Sack, J.S.; Rahma, O.E.; Hodi, F.S.; Zucker, S.D.; Grover, S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. *Hepatology* 2022, 75, 531–540. [CrossRef] [PubMed]

111. Le, S.; Chang, B.; Pham, A.; Chan, A. Impact of pharmacist-managed immune checkpoint inhibitor toxicities. *J. Oncol. Pharm. Pract.* 2021, 27, 596–600. [CrossRef]

112. Chennamadhavuni, A.; Abushahin, L.; Jin, N.; Presley, C.J.; Manne, A. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. *Front. Immunol.* 2022, 13, 779691. [CrossRef]